Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab + cabozantinib vs cabozantinib in RCC after ICI progression
2024-517785-42-00Phase 3Completed
- Sponsor
- Roche
- Start
- Nov 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 10
01
Overview
Phase 3, randomised, open-label trial in renal cell carcinoma (RCC) comparing Atezolizumab + cabozantinib with Cabozantinib monotherapy (2 arms). Primary endpoints: Progression-free survival as assessed by Independent Review Facility (IRF) and Overall survival. Started Nov 2024; status: completed.
02
Drugs
atezolizumabcabozantinib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on 2024-517785-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517785-42-00.